{
      "Rank": 414,
      "Acronym": [
            "HERA"
      ],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Single dose of 20 million Longeveron Mesenchymal Stem Cells (LMSCs) will be delivered followed by vaccination with Fluzone High-Dose at 1 week post-infusion.",
            "Single dose of 100 million Longeveron Mesenchymal Stem Cells (LMSCs) followed by vaccination with Fluzone High-Dose at either 1 week (Cohort B) or 4 weeks (Cohort C) post infusion.",
            "2 cohorts to receive a single infusion of 100 million Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort A: 30 subjects) or placebo (Cohort B:30 subjects) followed by vaccination with Fluzone High-Dose."
      ],
      "ArmGroupInterventionName": [
            "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
            "Biological: Fluzone High Dose Vaccine",
            "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
            "Biological: Fluzone High Dose Vaccine",
            "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
            "Biological: Fluzone High Dose Vaccine"
      ],
      "ArmGroupLabel": [
            "Pilot Phase- Cohort A",
            "Pilot Phase Cohort B & C",
            "Double-Blind,Randomized,Placebo Phase"
      ],
      "ArmGroupType": [
            "Experimental",
            "Experimental",
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT02982915"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "This is a phase I/II, randomized, blinded and placebo-controlled study to test the safety and efficacy of Lomecel-B for improving vaccine immune response."
      ],
      "BriefTitle": [
            "Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "June 2022"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Aging Frailty"
      ],
      "ConditionAncestorId": [
            "D000010335"
      ],
      "ConditionAncestorTerm": [
            "Pathologic Processes"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC23",
            "All"
      ],
      "ConditionBrowseBranchName": [
            "Symptoms and General Pathology",
            "All Conditions"
      ],
      "ConditionBrowseLeafAsFound": [
            "Frailty"
      ],
      "ConditionBrowseLeafId": [
            "M1175"
      ],
      "ConditionBrowseLeafName": [
            "Frailty"
      ],
      "ConditionBrowseLeafRelevance": [
            "high"
      ],
      "ConditionMeshId": [
            "D000073496"
      ],
      "ConditionMeshTerm": [
            "Frailty"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Double"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Investigator"
      ],
      "DetailedDescription": [
            "A pilot phase will consist of a 3 subject safety run-in, followed by 20 subject randomized phase to evaluate influenza vaccine response at 1 week and 4 weeks post infusion of Lomecel-B (Formerly LMSCs). This will be followed by a double-blinded, randomized, placebo-controlled phase."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nbe willing and able to provide written informed consent and comply with all procedures required by the protocol.\nbe 65 - 90 years of age at the time of signing the Informed Consent Form.\nhave a diagnosis of Aging Frailty, with a score of 4 to 7 using the Canadian Frailty Scale.\nhave a six-minute walk test (6MWT) distance of 200m - 400m for each of 2 trials, and the 2 trials must be within 15% of each other.\nhave total bilirubin between 0.3 - 1.9 mg/dL.\n\nExclusion Criteria:\n\nbe unwilling or unable to perform any of the assessments required by the Protocol.\nscore \u226424 on the Mini Mental State Examination (MMSE).\nhave previously received current year's flu-vaccine.\nhave any contraindication to receiving a vaccine.\nhave a Hemoglobin A1c (HbA1c) level >9.0%.\nbe diagnosed with malignancy (subjects without a recurrence in the last 2.5 years will be allowed) except curatively-treated basal cell carcinoma, melanoma in situ, or cervical carcinoma.\nhave a condition that projected to limit the life-expectancy to \u22641 year.\nhave autoimmune disease (e.g., rheumatoid arthritis).\nbe using medication(s) known to alter immune response, e.g., high-dose corticosteroids.\nhave HIV, AIDS, or other immunodeficiency.\n\ntest positive for hepatitis B virus\n\nIf the subject tests positive for anti-HBc or anti-HBs, they must be receiving treatment for Hepatitis B virus prior to infusion and remain on treatment throughout the study.\ntest positive for viremic hepatitis C, HIV1, HIV2, or syphilis.\nhave a resting blood oxygen saturation of <93% (measured by pulse oximetry).\nbe a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraception.\nhave documented current substance and/or alcohol abuse.\nhave known allergies to latex or eggs.\nhave a known hypersensitivity to dimethyl sulfoxide (DMSO).\nbe an organ transplant recipient (other than corneal, bone, skin, ligament, or tendon transplant).\nbe actively listed (or expected to be listed) for transplant of any organ (other than corneal, bone, skin, ligament, or tendon transplant).\n\nhave any clinically important abnormal screening laboratory values, including but not limited to:\n\nhemoglobin <10.0 g/dL.\nwhite blood cell count < 2500/mm3.\nplatelets < 100,000/mm3.\nprothrombin time/international normalized ratio (PT/INR) \u02c3 1.5 not due to a reversible cause (i.e. Coumadin).\naspartate transaminase, alanine transaminase, or alkaline phosphatase \u02c3 2 times upper limit of normal.\nhave a sitting or resting systolic blood pressure >180 mm Hg or diastolic blood pressure >110 mm Hg at Screening.\nhave any serious illness or any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the subject or preclude successful completion of the study, or that may compromise the validity of the study.\nbe currently participating in an investigational therapeutic or device trial, or have participated in an investigational therapeutic or device trial within the previous 30 days, or participate in any other clinical trial for the duration of the time that the subject actively participates in this trial."
      ],
      "EnrollmentCount": [
            "62"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Double-Blind,Randomized,Placebo Phase",
            "Pilot Phase Cohort B & C",
            "Pilot Phase- Cohort A",
            "Double-Blind,Randomized,Placebo Phase",
            "Pilot Phase Cohort B & C",
            "Pilot Phase- Cohort A"
      ],
      "InterventionBrowseBranchAbbrev": [
            "All"
      ],
      "InterventionBrowseBranchName": [
            "All Drugs and Chemicals"
      ],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [
            "M16512",
            "M9336",
            "M3377"
      ],
      "InterventionBrowseLeafName": [
            "Vaccines",
            "Immunoglobulins",
            "Antibodies"
      ],
      "InterventionBrowseLeafRelevance": [
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "Intravenously delivered",
            "Intramuscular injection"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "Longeveron Mesenchymal Stem Cells (LMSCs)",
            "Fluzone High Dose Vaccine"
      ],
      "InterventionOtherName": [
            "Lomecel-B"
      ],
      "InterventionType": [
            "Biological",
            "Biological"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "August 17, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "August 15, 2022"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "Longeveron Inc."
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Coral Gables",
            "Fort Myers",
            "Miami",
            "Miami",
            "Baltimore",
            "Rockville"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States"
      ],
      "LocationFacility": [
            "Clinical Research of South Florida",
            "Clinical Physiology Associates",
            "University of Miami",
            "Vista Health Research",
            "Johns Hopkins University",
            "Optimal Research LLC"
      ],
      "LocationState": [
            "Florida",
            "Florida",
            "Florida",
            "Florida",
            "Maryland",
            "Maryland"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "33134",
            "33912",
            "33136",
            "33176",
            "21224",
            "20850"
      ],
      "MaximumAge": [
            "90 Years"
      ],
      "MinimumAge": [
            "65 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Effects of Intravenous Delivery of Lomecel-B (Formerly Allogenic Longeveron Human Mesenchymal Stem Cells (LMSCs)) on VaccinE-Specific Antibody Responses in Subjects With Aging Frailty"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "Longeveron Inc."
      ],
      "OrgStudyId": [
            "00-0000-03"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [],
      "OverallOfficialName": [],
      "OverallOfficialRole": [],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "June 2021"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [
            "Is life-threatening (e.g., stroke or non-fatal pulmonary embolism).\nRequires inpatient hospitalization or prolongation of existing hospitalization.\nResults in persistent or significant disability/incapacity.\nResults in death\nResults in other clinically significant untoward laboratory test result(s) or medical condition(s), determined per Investigator's judgment.",
            "Measurements of validated hemagglutination inhibition (HAI) assays at follow up visits."
      ],
      "PrimaryOutcomeMeasure": [
            "The incidence of any treatment-emergent serious adverse event (TE-SAE), defined as one or more of the following untoward medical occurrences within 30 days after infusion as assessed by the following:",
            "The ability of Lomecel-B (LMSC) treatment to improve inactivation of influenza virus as assessed by validated hemagglutination inhibition (HAI) assays."
      ],
      "PrimaryOutcomeTimeFrame": [
            "30 days after infusion",
            "Baseline Visit, Vaccination Visits, Weeks 1, 2, 4, Month 6 and Month 12 Follow-Up Visits."
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "Plasma levels of interleukins measured in pg/mL.",
            "Change in Clinical Frailty rating",
            "Change in risk of falling",
            "Change in subject quality of life as assessed by participant-reported outcomes.",
            "Change in subject quality of life as assessed by participant-reported outcomes.",
            "Change in subject quality of life as assessed by participant-reported outcomes.",
            "Change in subject quality of life as assessed by participant-reported outcomes.",
            "Change in subject quality of life as assessed by participant-reported outcomes.",
            "Change in subject quality of life as assessed by participant-reported outcomes.",
            "Number of participants that die from any cause while enrolled on the trial and after being treated with LMSCs.",
            "Change by participant-reported outcomes. Minimum 16 (no concern about falling) to maximum 64 (severe concern about falling)",
            "Plasma levels of B & T Cells.",
            "Distance in meters walked in 6 minutes",
            "Short Physical Performance Battery Assessment",
            "TInetti POMA assessment",
            "Weigh measurements at visits",
            "Handgrip strength via dynamometer."
      ],
      "SecondaryOutcomeMeasure": [
            "Changes from baseline between the LMSC and placebo cohorts as assessed by plasma cytokine levels:",
            "Differences in rate of decline from Aging Frailty",
            "Assessed by the Falls Efficacy Scale-International and Performance Oriented Mobility Assessment",
            "PROMIS Short Form 20a questionnaire",
            "PROMIS Mobility questionnaire",
            "PROMIS Upper Extremity questionnaire",
            "Short Form 36 questionnaire",
            "IIEF questionnaire",
            "SQOL-F questionnaire",
            "Death from any cause",
            "Falls Efficacy Scale-International (FES-I)",
            "Changes from baseline between the LMSC and placebo cohorts as assessed by B & T cell levels:",
            "Rate of decline in Aging Frailty status as assessed by the 6 minute walk test",
            "Rate of decline in Aging Frailty status as assessed by the Short Physical Performance Battery (SPPB)",
            "Rate of decline in Aging Frailty status as assessed by the Tinetti POMA Test",
            "Rate of decline in Aging Frailty status as assessed by the Weight Loss",
            "Rate of decline in Aging Frailty status as assessed by the Handgrip Test"
      ],
      "SecondaryOutcomeTimeFrame": [
            "Baseline, month 6 and month 12 after infusion",
            "Baseline, month 6 and month 12 after infusion",
            "Baseline, month 6 and month 12 after infusion",
            "Baseline, month 6 and month 12 after infusion",
            "Baseline, month 6 and month 12 after infusion",
            "Baseline, month 6 and month 12 after infusion",
            "Baseline, month 6 and month 12 after infusion",
            "Baseline, month 6 and month 12 after infusion",
            "Baseline, month 6 and month 12 after infusion",
            "Within 12 months after infusion",
            "Baseline, month 6 and month 12 after infusion",
            "Baseline, month 6 and month 12 after infusion",
            "Baseline, month 6 and month 12 after infusion",
            "Baseline, month 6 and month 12 after infusion",
            "Baseline, month 6 and month 12 after infusion",
            "Baseline, month 6 and month 12 after infusion",
            "Baseline, month 6 and month 12 after infusion"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "November 2016"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "August 2022"
      ],
      "StdAge": [
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "December 6, 2016"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "November 17, 2016"
      ],
      "StudyFirstSubmitQCDate": [
            "December 1, 2016"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}